DE10338174A1 - Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit - Google Patents

Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit Download PDF

Info

Publication number
DE10338174A1
DE10338174A1 DE10338174A DE10338174A DE10338174A1 DE 10338174 A1 DE10338174 A1 DE 10338174A1 DE 10338174 A DE10338174 A DE 10338174A DE 10338174 A DE10338174 A DE 10338174A DE 10338174 A1 DE10338174 A1 DE 10338174A1
Authority
DE
Germany
Prior art keywords
combination
group
active
pharmaceutical preparation
dopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10338174A
Other languages
German (de)
English (en)
Inventor
Michael Dr. Horstmann
Frank Dr. Theobald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10338174(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to DE10338174A priority Critical patent/DE10338174A1/de
Priority to RU2005141214/15A priority patent/RU2397757C2/ru
Priority to PT04764129T priority patent/PT1656122E/pt
Priority to AT04764129T priority patent/ATE446744T1/de
Priority to MXPA06001815A priority patent/MXPA06001815A/es
Priority to NZ545593A priority patent/NZ545593A/en
Priority to KR1020067003176A priority patent/KR20060065692A/ko
Priority to CA2535063A priority patent/CA2535063C/en
Priority to ES04764129T priority patent/ES2335771T5/es
Priority to DK04764129.5T priority patent/DK1656122T4/da
Priority to DE502004010303T priority patent/DE502004010303D1/de
Priority to JP2006523588A priority patent/JP2007502795A/ja
Priority to EP04764129A priority patent/EP1656122B2/de
Priority to BRPI0412054-0A priority patent/BRPI0412054A/pt
Priority to US10/568,941 priority patent/US8980308B2/en
Priority to CNA2004800225495A priority patent/CN1832732A/zh
Priority to PCT/EP2004/009136 priority patent/WO2005018619A1/de
Priority to AU2004266063A priority patent/AU2004266063B2/en
Priority to PL04764129T priority patent/PL1656122T5/pl
Priority to SI200431317T priority patent/SI1656122T2/sl
Publication of DE10338174A1 publication Critical patent/DE10338174A1/de
Priority to ZA200509779A priority patent/ZA200509779B/en
Priority to IL173712A priority patent/IL173712A/en
Priority to JP2011275858A priority patent/JP5827114B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE10338174A 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit Withdrawn DE10338174A1 (de)

Priority Applications (23)

Application Number Priority Date Filing Date Title
DE10338174A DE10338174A1 (de) 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
SI200431317T SI1656122T2 (sl) 2003-08-20 2004-08-14 Transdermalni farmacevtski pripravki s kombinacijami učinkovin za zdravljenje Parkinsonove bolezni
DE502004010303T DE502004010303D1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
EP04764129A EP1656122B2 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
AT04764129T ATE446744T1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
MXPA06001815A MXPA06001815A (es) 2003-08-20 2004-08-14 Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson.
NZ545593A NZ545593A (en) 2003-08-20 2004-08-14 Transdermal pharmaceutical preparation comprising L-dopa or a dopamine agonist, and an anticholinerically active substance or an NMDA receptor agonist, for treating ParkinsonÆs disease
KR1020067003176A KR20060065692A (ko) 2003-08-20 2004-08-14 활성 물질 조합을 함유하는 파킨슨씨병 치료용 경피 약학적제제
CA2535063A CA2535063C (en) 2003-08-20 2004-08-14 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
ES04764129T ES2335771T5 (es) 2003-08-20 2004-08-14 Preparaciones farmacéuticas transdérmicas con combinaciones de principios activos para el tratamiento de la enfermedad de Parkinson
DK04764129.5T DK1656122T4 (da) 2003-08-20 2004-08-14 Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
RU2005141214/15A RU2397757C2 (ru) 2003-08-20 2004-08-14 Чрескожный лекарственный препарат для лечения болезни паркинсона, содержащий сочетания действующих веществ
JP2006523588A JP2007502795A (ja) 2003-08-20 2004-08-14 パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤
PT04764129T PT1656122E (pt) 2003-08-20 2004-08-14 Preparações medicamentosas para uma aplicação transdérmica contendo combinações de princípios activos para tratar a doença de parkinson
BRPI0412054-0A BRPI0412054A (pt) 2003-08-20 2004-08-14 preparação farmacêutica transdérmica
US10/568,941 US8980308B2 (en) 2003-08-20 2004-08-14 Transdermal pharmaceutical preparation containing active substance combinations, for treating Parkinson's disease
CNA2004800225495A CN1832732A (zh) 2003-08-20 2004-08-14 用于治疗帕金森氏症的含有活性物质组合的经皮药物制剂
PCT/EP2004/009136 WO2005018619A1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
AU2004266063A AU2004266063B2 (en) 2003-08-20 2004-08-14 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
PL04764129T PL1656122T5 (pl) 2003-08-20 2004-08-14 Transdermalne preparaty lecznicze zawierające połączenia substancji czynnych do leczenia choroby Parkinsona
ZA200509779A ZA200509779B (en) 2003-08-20 2005-12-02 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
IL173712A IL173712A (en) 2003-08-20 2006-02-13 Transdermal pharmaceutical preparation containing active substance combinations for treating parkinson's disease
JP2011275858A JP5827114B2 (ja) 2003-08-20 2011-12-16 パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10338174A DE10338174A1 (de) 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit

Publications (1)

Publication Number Publication Date
DE10338174A1 true DE10338174A1 (de) 2005-03-24

Family

ID=34201721

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10338174A Withdrawn DE10338174A1 (de) 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE502004010303T Expired - Lifetime DE502004010303D1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004010303T Expired - Lifetime DE502004010303D1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit

Country Status (21)

Country Link
US (1) US8980308B2 (enExample)
EP (1) EP1656122B2 (enExample)
JP (2) JP2007502795A (enExample)
KR (1) KR20060065692A (enExample)
CN (1) CN1832732A (enExample)
AT (1) ATE446744T1 (enExample)
AU (1) AU2004266063B2 (enExample)
BR (1) BRPI0412054A (enExample)
CA (1) CA2535063C (enExample)
DE (2) DE10338174A1 (enExample)
DK (1) DK1656122T4 (enExample)
ES (1) ES2335771T5 (enExample)
IL (1) IL173712A (enExample)
MX (1) MXPA06001815A (enExample)
NZ (1) NZ545593A (enExample)
PL (1) PL1656122T5 (enExample)
PT (1) PT1656122E (enExample)
RU (1) RU2397757C2 (enExample)
SI (1) SI1656122T2 (enExample)
WO (1) WO2005018619A1 (enExample)
ZA (1) ZA200509779B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
KR20190079705A (ko) * 2008-07-29 2019-07-05 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 화합물 및 그 약학적 조성물
RU2701731C2 (ru) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
US9017723B2 (en) 2010-04-30 2015-04-28 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP3604299B1 (en) 2011-12-13 2023-07-26 Bial-Portela & CA, S.A. Chemical compound useful as intermediate for preparing a catechol-0-methyl transferase inhibitor
US20130197023A1 (en) * 2012-01-27 2013-08-01 California Institute Of Technology Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors
NZ706590A (en) 2012-11-02 2016-02-26 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CN103622997A (zh) * 2013-11-22 2014-03-12 内蒙古医科大学 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物
EP2946775A1 (de) 2014-05-20 2015-11-25 LTS LOHMANN Therapie-Systeme AG Lavendelöl enthaltendes transdermales therapeutisches System
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
CN104510725B (zh) * 2015-01-22 2021-04-27 中国药科大学 一种普拉克索周效透皮贴剂及其制备方法
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2018067163A1 (en) * 2016-10-07 2018-04-12 Transwell Biotech Co., Ltd. Pramipexole transdermal delivery system and uses thereof
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
EP0404807B1 (en) * 1988-03-29 1993-06-30 Somerset Pharmaceuticals, Inc. Deprenyl for systemic transdermal administration
WO1996000062A1 (en) * 1994-06-27 1996-01-04 Interneuron Pharmaceuticals, Inc. Dopamine d1 agonists for the treatment of dementia
US20030082214A1 (en) * 2001-08-17 2003-05-01 Williams Robert O. Topical compositions and methods for treating pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
JPH0611698B2 (ja) 1984-12-19 1994-02-16 大正製薬株式会社 貼付剤
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
DE3710966A1 (de) 1986-04-16 1987-12-03 Degussa Synergistische kombination von amantadin und selegilin
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
HK1006281A1 (en) * 1992-07-28 1999-02-19 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
DE4332094C2 (de) * 1993-09-22 1995-09-07 Lohmann Therapie Syst Lts Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
IL122484A0 (en) 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
DE19626621A1 (de) 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
JPH11209271A (ja) 1998-01-23 1999-08-03 Nitto Denko Corp 経皮吸収製剤
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
DE60006069T2 (de) 1999-02-05 2004-07-29 Cipla Ltd. Topische sprays enthaltend eine filmbildende zusammensetzung
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
FR2798065B1 (fr) 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
JP2002097137A (ja) * 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10066158B4 (de) 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
DE10064453A1 (de) 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
EP1325742A1 (en) 2001-05-08 2003-07-09 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
ATE251901T1 (de) 2001-05-08 2003-11-15 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
EP0404807B1 (en) * 1988-03-29 1993-06-30 Somerset Pharmaceuticals, Inc. Deprenyl for systemic transdermal administration
WO1996000062A1 (en) * 1994-06-27 1996-01-04 Interneuron Pharmaceuticals, Inc. Dopamine d1 agonists for the treatment of dementia
US20030082214A1 (en) * 2001-08-17 2003-05-01 Williams Robert O. Topical compositions and methods for treating pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Amitriptyline" in: National Library of Medicine, Specialized Information Services. Im Internet< http://chem2.sis.nlm.nih.gov/chemidplus/jsp/ chemidlite/ChemFull.jsp> *

Also Published As

Publication number Publication date
JP2012092127A (ja) 2012-05-17
EP1656122B2 (de) 2012-11-28
AU2004266063B2 (en) 2010-04-08
RU2397757C2 (ru) 2010-08-27
US20070026054A1 (en) 2007-02-01
CN1832732A (zh) 2006-09-13
DE502004010303D1 (de) 2009-12-10
BRPI0412054A (pt) 2006-08-15
AU2004266063A1 (en) 2005-03-03
DK1656122T4 (da) 2013-03-11
US8980308B2 (en) 2015-03-17
CA2535063C (en) 2014-06-17
ZA200509779B (en) 2006-09-27
NZ545593A (en) 2009-09-25
SI1656122T1 (sl) 2010-02-26
EP1656122B1 (de) 2009-10-28
PL1656122T5 (pl) 2013-04-30
PL1656122T3 (pl) 2010-03-31
WO2005018619A1 (de) 2005-03-03
ATE446744T1 (de) 2009-11-15
SI1656122T2 (sl) 2013-03-29
ES2335771T3 (es) 2010-04-05
PT1656122E (pt) 2010-02-02
JP5827114B2 (ja) 2015-12-02
KR20060065692A (ko) 2006-06-14
RU2005141214A (ru) 2006-07-27
EP1656122A1 (de) 2006-05-17
MXPA06001815A (es) 2006-05-31
CA2535063A1 (en) 2005-03-03
JP2007502795A (ja) 2007-02-15
ES2335771T5 (es) 2013-03-26
IL173712A0 (en) 2006-07-05
IL173712A (en) 2010-11-30
DK1656122T3 (da) 2010-03-08

Similar Documents

Publication Publication Date Title
EP1656122B1 (de) Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
EP1313457B1 (de) Transdermales therapeutisches system zur abgabe von venlafaxin
DE60021099T2 (de) Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung
DE60311449T2 (de) Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
EP1651215A1 (de) Transdermales therapeutisches system mit dem wirkstoff pramipexol
DE102012013421A1 (de) Transdermales therapeutisches System (TTS) mit Rotigotin
DE10004790B4 (de) Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
EP0910379A1 (de) Pflaster zur transdermalen anwendung von pergolid
EP1368008B1 (de) Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol
DE102012013439A1 (de) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
EP0742716B1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
EP2366388A1 (de) Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
WO2016208729A1 (ja) ナルフラフィン含有経皮吸収貼付剤
WO2001080859A1 (de) Transdermale therapeutische systeme zur applikation von moxonidin
EP1235580A2 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
DE4229230C2 (de) Transdermales therapeutisches System mit Pentetrazol als Wirkstoff
EP3886821A1 (de) Transdermales therapeutisches system mit diffusionsbarriere
EP3697394A1 (de) Transdermales darreichungssystem enthaltend einen dopaminagonisten
EP3829550B1 (de) Transdermales therapeutisches system zur abgabe von scopolamin ohne membran
DE3843557A1 (de) Transdermales therapeutisches system zur verabreichung von clenbuterol
DE19908787A1 (de) Transdermale Applikation von ß2-Sympathomimetika zur Behandlung obstruktiver Atemwegserkrankungen
EP2946776A1 (de) Transdermales therapeutisches System zur Abgabe von Amitriptylin

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R082 Change of representative

Representative=s name: MICHALSKI HUETTERMANN & PARTNER PATENTANWAELTE, DE

R120 Application withdrawn or ip right abandoned